Treats infections caused by susceptible isolates of the designated microorganisms in the…. ANDA 211525, held by Amneal. Ofloxacin.
As of Nov 16, 2026, ANDA 211525 (Ofloxacin), held by Amneal, was first approved by FDA on Aug 30, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ofloxacin otic solution, 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus aureus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ofloxacin0.3% · solution/drops;otic | Ofloxacin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters